10-QPeriod: Q1 FY2023

STRYKER CORP Quarterly Report for Q1 Ended Mar 31, 2023

Filed May 2, 2023For Securities:SYK

Summary

Stryker Corporation reported strong first-quarter 2023 results, with net sales increasing by 11.8% to $4.78 billion, demonstrating robust top-line growth. This increase was driven by a balanced contribution from both the MedSurg and Neurotechnology and Orthopaedics and Spine segments, with constant currency growth of 14.0% highlighting operational strength. Diluted Earnings Per Share (EPS) saw a significant jump to $1.54, more than doubling from $0.84 in the prior year's quarter, reflecting improved profitability. The company also highlighted strategic progress, including the recent acquisition of Cerus Endovascular Limited, aimed at bolstering its neurovascular offerings. Despite facing ongoing macroeconomic challenges such as inflation and supply chain constraints, Stryker's management expressed confidence in its ability to navigate these headwinds, supported by solid operational execution and strategic investments. The company's financial condition remains strong, with ample liquidity to support ongoing operations and future growth initiatives.

Financial Highlights

51 data points
Beta

Revenue

$4.78B

63.1% Gross Margin

Net Income

$592.00M

12.4% Net Margin

EPS (Diluted)

$1.54

Total Assets

$36.83B

Cash & Equivalents

$1.67B

Free Cash Flow

$315.00M

Financial Statements
Beta
Revenue$4.78B
Cost of Revenue$1.76B
Gross Profit$3.02B
R&D Expenses$339.00M
SG&A Expenses$1.78B
Operating Expenses$2.28B
Operating Income$735.00M
Net Income$592.00M
EPS (Basic)$1.56
EPS (Diluted)$1.54
Shares Outstanding (Basic)379.00M
Shares Outstanding (Diluted)383.20M

Key Highlights

  • 1Net sales grew 11.8% to $4.78 billion, with constant currency growth of 14.0%, indicating strong underlying demand and effective pricing strategies.
  • 2Diluted EPS surged to $1.54 from $0.84 in the prior year, a substantial increase of 83.3%, signaling improved profitability.
  • 3Both major segments, MedSurg and Neurotechnology (+11.0%) and Orthopaedics and Spine (+12.7%), contributed to the overall sales growth, showcasing a diversified revenue stream.
  • 4Research, development, and engineering expenses decreased by 17.9%, primarily due to a higher spend in the prior year for product launches and intangible asset write-offs.
  • 5Stryker recently acquired Cerus Endovascular Limited for $300 million plus potential milestones, strengthening its position in the neurovascular market.
  • 6The company successfully managed operating income margin, which increased to 15.4% from 10.5% in the prior year, despite manufacturing and supply chain cost pressures.
  • 7Cash flow from operations significantly improved, reaching $445 million compared to $203 million in the same period last year, indicating better cash generation.

Frequently Asked Questions

Stryker's sales growth of 11.8% was driven by a combination of increased unit volume and higher prices. Specifically, unit volume increased due to higher product shipments across most MedSurg and Neurotechnology businesses and all Orthopaedics and Spine businesses. The company also benefited from higher pricing, contributing to the overall revenue increase.

The acquisition of Cerus Endovascular Limited, completed shortly after the quarter end on May 2, 2023, is expected to strengthen Stryker's Neurovascular business within the MedSurg and Neurotechnology segment. The deal involved an upfront payment of $300 million and up to $225 million in future milestone payments, reflecting a strategic move to expand offerings in the treatment of hemorrhagic stroke.

Stryker continues to navigate macroeconomic challenges including inflationary pressures, labor shortages, and supply chain disruptions, particularly impacting capital products due to electronic component shortages. The company is also contending with China's volume-based procurement programs for medical consumables, which have negatively impacted commercial operations for certain products in that region, leading to an exit from the spine business in China.

Stryker demonstrated significant improvement in profitability. Net earnings increased by 83.3% to $592 million, and diluted EPS more than doubled to $1.54 from $0.84 in the prior year's quarter. The adjusted diluted EPS also grew by 8.6% to $2.14. This improvement was driven by strong sales growth and effective cost management, despite some pressures on gross margins from manufacturing and supply chain costs.